28 results
8-K
EX-99.1
INVA
Innoviva Inc
22 Apr 14
Breo™Ellipta® (fluticasone furoate/vilanterol trifenatate) approved in Australia for Asthma and Chronic Obstructive Pulmonary Disease
12:00am
. As with all ICS therapy, patients should rinse their mouth with water after use to minimise the local adverse effects. To minimise adverse reactions
8-K
EX-99
INVA
Innoviva Inc
30 Oct 13
Other Events
12:00am
their mouth with water without swallowing after inhalation to help reduce this risk.
An increase in the incidence of pneumonia has been observed in subjects
8-K
EX-99
INVA
Innoviva Inc
13 Mar 14
Other Events
12:00am
.
Oropharyngeal candidiasis has occurred in patients treated with Breo Ellipta. Patients should rinse their mouth with water without swallowing after
8-K
EX-99
INVA
Innoviva Inc
6 Dec 13
Other Events
12:00am
.
Oropharyngeal candidiasis has occurred in patients treated with Breo Ellipta. Patients should rinse their mouth with water without swallowing after
8-K
EX-99.2
ogtt6ya 1o
1 Dec 14
Anoro® Ellipta® (umeclidinium/vilanterol) to be reimbursed in Australia for Chronic Obstructive Pulmonary Disease
12:00am
S-1
EX-10.10
trrw w9r51ww
21 Mar 00
IPO registration
12:00am
8-K
EX-99.1
zx7uku3z6s31
9 Apr 14
Regulation FD Disclosure
12:00am
8-K
EX-99
xif b2vdzh
6 Feb 14
Results of Operations and Financial Condition
12:00am
SC TO-C
EX-2.1
8itkok4
11 Jul 22
Information about tender offer
3:46pm
8-K
EX-2.1
n199ozh4otghtr pl6w
11 Jul 22
Innoviva to Acquire La Jolla Pharmaceutical Company
7:38am
S-3ASR
EX-1.1
ztqpyvojl pqenyb4y
30 Jan 06
Automatic shelf registration
12:00am
8-K
EX-1.1
8kjysk5xdxk71ay50 ug
23 Jan 08
Theravance Announces Pricing of Convertible Subordinated
12:00am